There was a mistake in Figure 1 as published. During the preparation of the figure, an incorrect merged image was inadvertently used for the control (con) group, which resulted in the control group panel not accurately representing the intended experimental condition. The corrected Figure 1 appears below.
FIGURE 1.
Celastrol exhibits anti-necroptotic activity (A) Chemical structure of celastrol (B) HT-29 cells were treated with different concentrations of celastrol, followed by TSZ stimulation for 12 h. Cell viability was measured using the CellTiter-Lumi™ luminescent assay (C) Half-maximal effective concentration (EC50) value calculated based on cell viability results (D) HT-29 cells were pre-treated with various concentrations of celastrol before TSZ stimulation for 12 h. LDH release was measured using an LDH assay kit (E) Representative calcein-AM/PI staining images of HT-29 cells treated with celastrol for 12 h under different conditions. ** P < 0.01, * P < 0.05 versus the TSZ group; ## P < 0.01, # P < 0.05 versus the CON group. N = 3 per group.
The original version of this article has been updated.
Footnotes
Edited and reviewed by: Yinan Zhang, Nanjing University of Chinese Medicine, China
Generative AI statement
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.